摘要:
The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.
摘要:
The invention relates to two mutant proteins of the fusion protein (F protein) of the Parainfluenza virus (PIV) currently recorded as type-5 PFV (PIV-5 or PIV5) and type-2 PIV (PIV-2 or PIV2). The present invention relates to products derived therefrom such as: nucleic acids, vectors, cells; fusion inhibitors of the antibody, aptamers, interfering RNA; myelomae, hybridomae, progenitor and stem cells. The present invention also relates to said mutant proteins and products derived therefrom used in medical applications and biotechnologies.
摘要:
The invention relates to a phylogenetic group variant of HPIV2, in particular to a phylogenetic sub-group variant of HPIV2. The invention further relates to diagnostic means for HPIV2, taking account of said group and sub-group.
摘要翻译:新型人类副流感病毒2型(HPIV2)变体(I)属于不包括Greer,Toshiba,V98和V94分离物的亚组,并且具有在本说明书中给出的五个定义的氨基酸序列之一的F蛋白和/或HN 蛋白质与说明书中给出的四个限定的氨基酸序列之一。 新型人类副流感病毒2型(HPIV2)变体(I)属于不包括格雷尔,东芝,V98和V94分离物的亚组,并且具有SEQ ID NO:24,29,34,39或44之一的F蛋白( 和/或具有SEQ ID NO:26,31,36或41之一(在说明书中给出的限定的氨基酸序列)之一的HN蛋白。 还包括独立权利要求:(1)(I)的基因组RNA及其cDNA逆转录物; (2)(I)的包膜蛋白; (3)编码包膜蛋白的核酸; (4)包含(I)的F或HN蛋白编码序列的至少132个核苷酸的核酸; (5)引物对,其包含SEQ ID NO:62-66,67-70或83-86(在说明书中给出的确定的核苷酸序列)的14-30个核苷酸的5'片段和14-30个核苷酸的5'片段 与SEQ ID NO:62-66,67-70或83-86互补的序列; (6)如上所述包含至少一个引物对的引物组; (7)如上所述形成引物对的一部分的引物; (8)用于通过如上所述的引物对实时扩增来特异性检测(I)的探针(P1),其包含SEQ ID NO:62-66,67-70或83-86的14-30个核苷酸的片段或其 补充; (9)用于诊断呼吸障碍或感染的试剂盒,其包含如上所述的引物对和/或探针; (10)探针(P2),其包含SEQ ID NO:57-61或71-82之一(说明书中给出的确定的核苷酸序列)或其互补序列的片段; (11)包含探针P2的固体微流体支持物; (12)结合(I)的包膜蛋白但不与Greer NC003443分离物的包膜蛋白结合的抗体; (13)用于诊断呼吸障碍或感染的试剂盒,其包含如上所述的抗体。
摘要:
The invention relates to mutant proteins of the fusion protein (F protein) of the Parainfluenza virus (PIV) currently recorded as type-5 PIV (PIV-5 or PIV5) and type-2 PIV (PIV-2 or PIV2). The present invention relates to products derived therefrom such as: nucleic acids, vectors, cells; fusion inhibitors of the antibody, aptamers, interfering RNA; myelomae, hybridomae, progenitor and stem cells. The present invention also relates to said mutant proteins and products derived therefrom used in medical applications and biotechnologies.